Foundayo vs Zepbound: A Daily Pill or a Weekly Tirzepatide Shot?

Foundayo vs Zepbound is a trade between convenience and size of effect. On the FDA labels, adults without diabetes on the top dose of Zepbound lost an average of 20.9% of body weight over 72 weeks, against 3.1% on placebo. Adults on the top dose of Foundayo lost 11.1%, against 2.1%, over the same 72 weeks (Foundayo prescribing information).

Foundayo, the brand name for orforglipron, is a once-daily tablet. Zepbound, the brand name for tirzepatide, is a once-weekly injection. Both are FDA-approved for chronic weight management, and no trial has compared them directly. If needles are the reason you have not started treatment, Foundayo removes them. If the size of the result matters most to you, tirzepatide has the stronger numbers.

The Wegovy pill vs Zepbound question turns on the same trade: oral semaglutide, approved in December 2025, sits between the two on weight loss and carries strict empty-stomach rules.

Both drugs act on the GLP-1 receptor, the target behind the appetite effect many patients describe as food noise going quiet.

Foundayo: a small-molecule pill

Orforglipron is a small-molecule, nonpeptide GLP-1 receptor agonist, designed to be swallowed rather than injected (NEJM, 2025). FDA approved it as Foundayo on April 1, 2026. Its label states that food has no clinically relevant effect on absorption, so there is no fasting window and no water limit.

It acts on one receptor only, and FDA's approval announcement described it as a GLP-1 receptor partial agonist pill that does not need to be taken on an empty stomach (FDA).

Zepbound: a dual-receptor injection

Tirzepatide activates both the GIP and GLP-1 receptors. That second receptor is the main reason its trial numbers run higher, as our guide to how tirzepatide works explains. Zepbound comes in single-dose pens, single-dose or multi-dose vials and a four-dose KwikPen, injected once a week at any time of day.

Each drug was tested against placebo in its own 72-week trial, so read the gap as a direction rather than an exact measurement.

Foundayo in ATTAIN-1

ATTAIN-1 enrolled 3,127 adults with obesity, or with overweight and a related condition, and no diabetes. Mean weight change was 7.4% on 5.5 mg, 8.3% on 9 mg and 11.1% on 17.2 mg, against 2.1% on placebo. At the top dose, 54.5% lost at least 10% of their body weight and 18.4% lost at least 20%. In adults with type 2 diabetes, the top dose produced 9.6%.

Zepbound in SURMOUNT-1

SURMOUNT-1 enrolled 2,539 adults without diabetes. Mean weight change was 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo. At 15 mg, 83.5% lost at least 10% and 56.7% lost at least 20% (Zepbound prescribing information). In adults with type 2 diabetes, 15 mg produced 14.7%.

No head-to-head trial

No registered trial pits orforglipron against tirzepatide for weight loss (ClinicalTrials.gov). A 2026 network meta-analysis in The BMJ, drawing on 262 trials, put one-year weight loss beyond lifestyle change at 14.9% for tirzepatide and 9.9% for orforglipron (BMJ, 2026). That indirect evidence points the same way as the labels.

Scroll the table sideways to see both columns →

The Wegovy pill is semaglutide in a 25 mg daily tablet, approved for weight management on December 22, 2025. In its 64-week trial, adults lost 13.6% of body weight on average, against 2.4% on placebo, and the tablet carries the cardiovascular risk-reduction indication of injectable Wegovy (Wegovy prescribing information). The routine is the catch.

You take it in the morning on an empty stomach with no more than 4 ounces of water, then wait at least 30 minutes before food, other drinks or other pills.

For the Wegovy pill vs Zepbound question, the only direct evidence involves injectable Wegovy. In SURMOUNT-5, tirzepatide produced 20.2% average weight loss against 13.7% for injectable semaglutide over 72 weeks (NEJM, 2025). Our comparison of the Wegovy pill vs Wegovy injection covers the semaglutide side.

Stomach and gut effects dominate for both drugs, and Foundayo's rates ran a little higher.

Any gastrointestinal side effect was reported by 60% to 69% of people on Foundayo, against 37% on placebo, and by 56% on Zepbound, against 30%. Nausea affected 26% to 35% on Foundayo and 25% to 29% on Zepbound. Vomiting reached 24% at Foundayo's top dose and 13% at Zepbound's. Discontinuation for side effects ran 8% on Foundayo, against up to 6.7% on Zepbound, and Foundayo raised heart rate by 4 to 5 beats per minute on average.

Warnings they share

Both carry a boxed warning for thyroid C-cell tumors, and neither is prescribed to anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Both labels warn about pancreatitis, gallbladder problems and dehydration-related kidney injury, and both drugs should be stopped if you become pregnant.

Where Foundayo needs more checking

Foundayo interacts with drugs that act on the liver enzyme CYP3A4. Its label caps the dose at 9 mg alongside strong CYP3A4 inhibitors, advises against some other combinations, and limits simvastatin to 20 mg a day. Both drugs ask anyone on oral birth control to add a backup method after starting and after each dose increase, as our guide to tirzepatide and birth control explains.

One trial has tested this move. In ATTAIN-MAINTAIN, adults who had lost weight on tirzepatide were switched to daily orforglipron or to placebo for a year. Those on orforglipron kept 74.7% of the weight they had lost, against 49.2% for those on placebo (Nature Medicine, 2026).

The trial had no group that stayed on tirzepatide, so it shows that the pill held more weight off than stopping did, not that the pill holds weight off as well as staying on the shot.

Switching is a clinical decision your prescriber makes with you.

At its April 2026 launch, Foundayo's cash price was reported at $149 to $349 a month (CNBC). The Wegovy pill launched in January 2026 at $149 for the starting dose and $299 a month for the 9 mg and 25 mg tablets (CNBC). Zepbound's self-pay price starts at $299 a month for the lowest dose, as reported in February 2026 (CNBC). Higher doses cost more, and manufacturer pricing changes often.

Harbor's tirzepatide program starts at $149 a month, and the price does not rise with your dose. It is compounded tirzepatide, prepared by a licensed U.S. pharmacy for you by name, and it is not FDA-approved. Our article on compounded tirzepatide in 2026 covers what that means.

Harbor's weight-loss programs use compounded tirzepatide and semaglutide. Neither Foundayo nor the Wegovy pill is an Harbor program, but the way Harbor's clinicians weigh a pill against a shot applies either way.

A daily pill may suit you when

• Injections are the reason you have not started treatment
• You want a daily routine with no fasting window or water limit
• A smaller average effect is an acceptable price for no needles

Weekly tirzepatide may suit you when

• The size of the result matters most to you
• You have obstructive sleep apnea with obesity, an approved use of tirzepatide
• You take simvastatin above 20 mg or a strong CYP3A4 inhibitor
• One dose a week fits your life better than a pill every day